Dillard’s, Inc. Reports Second Quarter and Year-to-Date Results LITTLE ROCK, Ark., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Dillard’s, Inc. (NYSE: DDS) (the “Company” or “Dillard’s”) announced operating results for the 13 and 26 weeks ended August 2, 2025. This release contains certain forward-looking statements. Please refer to the Company’s cautionary statements included below under “Forward-Looking Information.” Dillard’s Chief Executive Officer William T. Dillard, II commented on the quarter, “We were happy to achieve a sales increase for the first time in a while and encouraged by streng...
Dillard’s, Inc. to Report Second Quarter and Year-to-Date Results LITTLE ROCK, Ark., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Dillard’s, Inc. (DDS: NYSE) will announce results for the 13 and 26 weeks ended August 2, 2025 tomorrow before the open of the New York Stock Exchange. Contact: Julie J. GuymonDirector of Investor Relations(501) 376-5965
A director at SunOpta Inc sold 47,500 shares at 6.220USD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
H&R Block Reports Fiscal 2025 Results and Provides Fiscal 2026 Outlook - Delivered Revenue Growth of 4% and Earnings per Share Growth of 7% - - Returned $600 Million to Shareholders via Dividends and Share Repurchases - - Increases Quarterly Dividend by 12% - KANSAS CITY, Mo., Aug. 12, 2025 (GLOBE NEWSWIRE) -- H&R Block, Inc. (NYSE: HRB) (the "Company") today released financial results1 for its fiscal 2025 year ended June 30, 2025. "Fiscal 2025 marked another year of meaningful progress in our transformation journey, with strong revenue growth, disciplined capital allocati...
Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900 The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced solid tumors whose cancers harbor specific genetic alterations, and in combination with EGFR and ALK inhibitors in patients with NSCLC whose cancers developed resistance to these treatments Nuvectis will hold a conference call tomorrow, Tuesday, August 12 at 8:30 AM ET to discuss the elements of the Phase 1b program and the overall market opportunity for NXP900 Fort Lee, NJ, Aug. 11, 2025 (G...
H&R Block, Inc. Announces Leadership Succession Plan Jeffrey J. Jones II to Retire After Eight Years; Will Remain Strategic AdvisorCurtis Campbell, President of Global Consumer Tax and Chief Product Officer at H&R Block, Named CEO-ElectAppointment Comes After Rigorous Succession Planning Process KANSAS CITY, Mo., Aug. 11, 2025 (GLOBE NEWSWIRE) -- H&R Block, Inc. (NYSE: HRB) (the "Company”) today announced that Jeffrey J. Jones II has informed the Board of Directors of his intention to retire as President and CEO of H&R Block on December 31, 2025, and will remain on the Board until su...
H&R Block Welcomes New Senior Leadership KANSAS CITY, Mo., Aug. 07, 2025 (GLOBE NEWSWIRE) -- H&R Block, Inc. (NYSE: HRB), a leading provider of global tax preparation, financial products and small business solutions, today announced Jason Lenhart as Senior Vice President and Chief Technology Officer, and Monika Mehrotra as Senior Vice President, Operations & Technology. The leaders will help accelerate the company’s transformation, elevating its financial services and building on its 70-year legacy of empowering financial freedom for clients through trust and technology. “Jason and Monik...
RCM Technologies, Inc. Announces Second Quarter Results PENNSAUKEN, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- RCM Technologies, Inc. (NasdaqGM: RCMT), a premier provider of solutions designed to enhance the operational performance of its customers through the deployment of advanced engineering, specialty health care, and information technology services, today announced financial results for the thirteen and twenty-six weeks ended June 28, 2025. RCM Technologies reported revenue of $78.2 million for the thirteen weeks ended June 28, 2025 (the current quarter), an increase of 13.0% compared ...
Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights NXP900 becomes the lead drug candidate after successfully completing the Phase 1a dose escalation study in patients with advanced solid tumors and a drug-drug interaction study in healthy volunteers; initiation of Phase 1b program is imminentStrengthened cash position following a July At-The-Market (ATM) shares acquisition by a healthcare-dedicated institutional investor; June 30, 2025 proforma cash position of approximately $39 million FORT LEE, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Nuvectis Ph...
In this installment of our Autumn for Broadband series, we provide a quick update on trends in the broadband market based on what we have seen from the companies that have reported so far. Net adds remained nearly flat compared to a year ago (when adjusted for ACP impact) but were within the pre-pandemic norm. Industry subscriber trends have mostly stabilized over the past 3 quarters, but y/y growth remains below pre-pandemic levels.
RCM Technologies, Inc. Announces Conference Call PENNSAUKEN, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- RCM Technologies, Inc. (NasdaqGM: RCMT) will hold a conference call on Thursday, August 7, 2025 at 11:30 a.m. Eastern time to discuss the financial results for the thirteen and twenty-six weeks ended June 28, 2025. The teleconference dial-in numbers are (888) 272-8703 for domestic callers and (713) 936-6995 for international callers. About RCM RCM Technologies (NasdaqGM: RCMT) is a business and technology solutions provider with world-class talent in key market segments. We help design...
Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study Available data from 13 patients with recurrent, platinum resistant, ARID1a-mutated ovarian cancer treated with 75 mg/day in the NXP800 Phase 1b study includes 2 partial responses and 3 stable diseases; thrombocytopenia successfully managed with intermittent dosing schedule; observed clinical activity warrants exploration of potential development opportunities in other cancer types NXP900 successfully completed a clinical...
Dillard’s and Pandora Celebrate Pandora’s 100th Dillard’s Location LITTLE ROCK, Ark., July 31, 2025 (GLOBE NEWSWIRE) -- Dillard’s, Inc. (“Dillard’s” or “the Company”) (NYSE: DDS) and Pandora, the world’s largest jewelry brand, celebrate the brand’s 100th Dillard’s location at the Company’s brand-new Battlefield Mall store in Springfield, Missouri. The successful collaboration began with the introduction of Pandora in more than 15 Dillard's stores in the fall of 2024. After an overwhelmingly positive response from Dillard’s customers, the companies rapidly expanded the offering to 99 lo...
H&R Block to Release Fiscal 2025 Results on August 12, 2025 KANSAS CITY, Mo., July 29, 2025 (GLOBE NEWSWIRE) -- H&R Block, Inc. (NYSE: HRB) will report fourth quarter and fiscal 2025 full year results on Tuesday August 12, 2025, after the New York Stock Exchange market close. At that time, a copy of the press release and presentation will be available on the company's investor relations website at . A conference call for analysts, institutional investors, and shareholders will be held at 4:30 p.m. Eastern time on Tuesday, August 12, 2025. During the conference call the company will give ...
Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies Drug-drug interaction (“DDI”) clinical studies help identify the potential for side effects, or in some cases, reduced therapeutic efficacy, that may be caused by interactions between different drugs.The market leading epidermal growth factor receptor (“EGFR”) and anaplastic lymphoma kinase (“ALK”) inhibitors for the treatment of non-small cell lung cancer (“NSCLC”) are substrates of the Cytochrome P450 (“CYP”...
RCM Technologies, Inc. has been Added to Membership of the US Small-Cap Russell 2000® Growth Index PENNSAUKEN, N.J., July 01, 2025 (GLOBE NEWSWIRE) -- RCM Technologies, Inc. (NasdaqGM: RCMT), a premier provider of solutions designed to enhance the performance of its clients through the deployment of advanced engineering, specialty healthcare, and technology services, was added to the broad-market Russell 3000® and small-cap Russell 2000® Indexes, effective after the US market opened on June 30 as part of the 2025 Russell Indexes reconstitution. “We have reached a significant milestone re...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.